内容紹介
Summary
At present, surgery is still the recommended principal treatment for breast cancer. However, there are conditions in which surgery is not suitable, for example in elderly or high-risk patients and those who do not wish to undergo the procedure. This study presents a case series of 8 patients with unresected breast cancer who were administered hormonal therapy as an optional treatment. Patients included in the study were diagnosed with StageⅠ-Ⅲ breast cancer from 2012 to 2015 at our institution. The patients were administered hormonal therapy for an average duration of 20.1 months. Complete responses were seen in 4 patients, while 1 and 3 patients were noted to have a partial response and stable disease, respectively. No disease progression was seen in any patients during the study period. Endocrine therapy may be an effective and safe option for patients with unresected breast cancer.
要旨
ホルモン受容体陽性乳癌の手術拒否・不適格例では,有害事象が少なく,長期投与が可能な内分泌療法が選択されることがある。今回,2012～2015年に当科および関連施設においてホルモン受容体陽性乳癌と診断され,非切除かつ内分泌療法を施行したStageⅠ～Ⅲの8例を対象とし,内分泌療法の意義について検討した。平均治療期間は20.1か月であり,治療を中断した症例はなかった。またPDとなった症例はなく,手術拒否・不適格例においては内分泌療法も有用・安全な選択肢であると考えられた。
目次
At present, surgery is still the recommended principal treatment for breast cancer. However, there are conditions in which surgery is not suitable, for example in elderly or high-risk patients and those who do not wish to undergo the procedure. This study presents a case series of 8 patients with unresected breast cancer who were administered hormonal therapy as an optional treatment. Patients included in the study were diagnosed with StageⅠ-Ⅲ breast cancer from 2012 to 2015 at our institution. The patients were administered hormonal therapy for an average duration of 20.1 months. Complete responses were seen in 4 patients, while 1 and 3 patients were noted to have a partial response and stable disease, respectively. No disease progression was seen in any patients during the study period. Endocrine therapy may be an effective and safe option for patients with unresected breast cancer.
要旨
ホルモン受容体陽性乳癌の手術拒否・不適格例では,有害事象が少なく,長期投与が可能な内分泌療法が選択されることがある。今回,2012～2015年に当科および関連施設においてホルモン受容体陽性乳癌と診断され,非切除かつ内分泌療法を施行したStageⅠ～Ⅲの8例を対象とし,内分泌療法の意義について検討した。平均治療期間は20.1か月であり,治療を中断した症例はなかった。またPDとなった症例はなく,手術拒否・不適格例においては内分泌療法も有用・安全な選択肢であると考えられた。